1
|
Grewal DS, Wykoff CC, D’Souza D, Jehl V, Alecu I, Jaffe GJ. Imaging Features of Retinal Vasculitis and/or Retinal Vascular Occlusion after Brolucizumab Treatment in the Postmarketing Setting. Ophthalmol Sci 2024; 4:100361. [PMID: 37869023 PMCID: PMC10587630 DOI: 10.1016/j.xops.2023.100361] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Figures] [Subscribe] [Scholar Register] [Received: 01/30/2023] [Revised: 06/01/2023] [Accepted: 06/23/2023] [Indexed: 10/24/2023]
Abstract
Purpose The aim of this analysis was to characterize the spectrum of inflammatory changes arising from brolucizumab use in routine clinical practice. Design Retrospective analysis of fluorescein angiography (FA), fundus photography (FP) and OCT images taken at the time of adverse event. Subjects Brolucizumab-treated patients with neovascular age-related macular degeneration with retinal vasculitis (RV) and/or retinal vascular occlusion (RO) reported to Novartis Patient Safety between February 2020 and January 2021. Methods Ocular images were reviewed by an external reading center using predefined grading lists for FA, FP, and OCT. Main Outcome Measures Classification of images, the most common imaging features of RV and/or RO by each imaging modality, and the anatomical location of the adverse event in relation to the macula. Results Gradable images (N = 475; 222 eyes; 198 patients) were classified as RV only (n = 72); RO only (n = 9), RV + RO (n = 63); posterior segment intraocular inflammation (n = 31); or none by imaging (n = 47). Of the 144 eyes with RV and/or RO, the most common imaging features were vascular leakage on FA, perivascular sheathing on FP, and hyperreflective dots in the vitreous humor on OCT. Retinal vascular occlusion was mainly branched and arterial, affecting multiple vessels. Conclusions Although no distinct inflammatory phenotype pathognomonic to brolucizumab-related inflammation was identified, this study increases our understanding of the spectrum of posterior segment inflammatory changes that may occur in brolucizumab-treated neovascular age-related macular degeneration patients, highlighting the potential value of widefield retinal imaging and angiography to detect these inflammatory adverse events. Financial Disclosures Proprietary or commercial disclosure may be found after the references.
Collapse
Affiliation(s)
- Dilraj S. Grewal
- Department of Ophthalmology, Duke University, Durham, North Carolina
| | | | - Divya D’Souza
- Novartis Pharmaceuticals Corp., East Hanover, New Jersey
| | | | | | - Glenn J. Jaffe
- Department of Ophthalmology, Duke University, Durham, North Carolina
| |
Collapse
|
2
|
Retson L, Tiwari N, Vaughn J, Bernes S, Adelson PD, Mansfield K, Libertini S, Kuzmiski B, Alecu I, Gabriel R, Mangum R. Epithelioid neoplasm of the spinal cord in a child with spinal muscular atrophy treated with onasemnogene abeparvovec. Mol Ther 2023; 31:2991-2998. [PMID: 37598295 PMCID: PMC10556221 DOI: 10.1016/j.ymthe.2023.08.013] [Citation(s) in RCA: 3] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/07/2023] [Revised: 08/02/2023] [Accepted: 08/17/2023] [Indexed: 08/21/2023] Open
Abstract
Spinal muscular atrophy is an autosomal recessive disease resulting in motor neuron degeneration and progressive life-limiting motor deficits when untreated. Onasemnogene abeparvovec is an adeno-associated virus serotype 9-based gene therapy that improves survival, motor function, and motor milestone achievement in symptomatic and presymptomatic patients. Although the adeno-associated virus genome is maintained as an episome, theoretical risk of tumorigenicity persists should genomic insertion occur. We present the case of a 16-month-old male with spinal muscular atrophy who was diagnosed with an epithelioid neoplasm of the spinal cord approximately 14 months after receiving onasemnogene abeparvovec. In situ hybridization analysis detected an onasemnogene abeparvovec nucleic acid signal broadly distributed in many but not all tumor cells. Integration site analysis on patient formalin-fixed, paraffin-embedded tumor samples failed to detect high-confidence integration sites of onasemnogene abeparvovec. The finding was considered inconclusive because of limited remaining tissue/DNA input. The improved life expectancy resulting from innovative spinal muscular atrophy therapies, including onasemnogene abeparvovec, has created an opportunity to analyze the long-term adverse events and durability of these therapies as well as identify potential disease associations that were previously unrecognized because of the premature death of these patients.
Collapse
Affiliation(s)
- Laura Retson
- Center for Cancer and Blood Disorders, Phoenix Children's Hospital, Phoenix, AZ 85016, USA
| | - Nishant Tiwari
- Pathology & Laboratory Medicine, Phoenix Children's Hospital, Phoenix, AZ 85016, USA
| | - Jennifer Vaughn
- Department of Radiology, Phoenix Children's Hospital, Phoenix, AZ 85016, USA
| | - Saunder Bernes
- Department of Neurology, Phoenix Children's Hospital, Phoenix, AZ 85016, USA
| | - P David Adelson
- Department of Neurosurgery, Rockefeller Neuroscience Institute, West Virginia University, Morgantown, WV 26506, USA
| | - Keith Mansfield
- Novartis Institutes for BioMedical Research, Cambridge, MA 02139, USA
| | - Silvana Libertini
- Novartis Institutes for BioMedical Research, Cambridge, MA 02139, USA
| | - Brent Kuzmiski
- Novartis Institutes for BioMedical Research, Cambridge, MA 02139, USA
| | - Iulian Alecu
- Novartis Pharmaceuticals, 4056 Basel, Switzerland
| | | | - Ross Mangum
- Center for Cancer and Blood Disorders, Phoenix Children's Hospital, Phoenix, AZ 85016, USA; Department of Child Health, University of Arizona College of Medicine, Phoenix, AZ, USA; Creighton University School of Medicine, Phoenix, AZ 85012, USA; Mayo Clinic Alix School of Medicine, Phoenix, AZ 85054, USA.
| |
Collapse
|
3
|
Lone MA, Santos T, Alecu I, Silva LC, Hornemann T. 1-Deoxysphingolipids. Biochim Biophys Acta Mol Cell Biol Lipids 2019; 1864:512-521. [PMID: 30625374 DOI: 10.1016/j.bbalip.2018.12.013] [Citation(s) in RCA: 56] [Impact Index Per Article: 11.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/05/2018] [Revised: 12/19/2018] [Accepted: 12/20/2018] [Indexed: 12/14/2022]
Abstract
Sphingolipids (SLs) are fundamental components of eukaryotic cells. 1-Deoxysphingolipids differ structurally from canonical SLs as they lack the essential C1-OH group. Consequently, 1-deoxysphingolipids cannot be converted to complex sphingolipids and are not degraded over the canonical catabolic pathways. Pathologically elevated 1-deoxySLs are involved in several disease conditions. Within this review, we will provide an up-to-date overview on the metabolic, physiological and pathophysiological aspects of this enigmatic class of "headless" sphingolipids.
Collapse
Affiliation(s)
- M A Lone
- Institute for Clinical Chemistry, University Hospital Zurich, Switzerland; Zurich Center for Integrative Human Physiology (ZIHP), University of Zurich, Switzerland
| | - T Santos
- Institute for Clinical Chemistry, University Hospital Zurich, Switzerland; Zurich Center for Integrative Human Physiology (ZIHP), University of Zurich, Switzerland; iMed.ULisboa - Research Institute for Medicines, Faculdade de Farmácia, Universidade de Lisboa, Av. Prof. Gama Pinto, 1649-003 Lisboa, Portugal; Centro de Química-Física Molecular and IN-Institute of Nanoscience and Nanotechnology, Instituto Superior Técnico, Universidade de Lisboa, Lisboa, Portugal
| | - I Alecu
- Neural Regeneration Laboratory, India Taylor Lipidomic Research Platform, Department of Biochemistry, Microbiology and Immunology, Ottawa Institute of Systems Biology, Ottawa Brain and Mind Research Institute, University of Ottawa, Canada
| | - L C Silva
- iMed.ULisboa - Research Institute for Medicines, Faculdade de Farmácia, Universidade de Lisboa, Av. Prof. Gama Pinto, 1649-003 Lisboa, Portugal; Centro de Química-Física Molecular and IN-Institute of Nanoscience and Nanotechnology, Instituto Superior Técnico, Universidade de Lisboa, Lisboa, Portugal
| | - T Hornemann
- Institute for Clinical Chemistry, University Hospital Zurich, Switzerland; Zurich Center for Integrative Human Physiology (ZIHP), University of Zurich, Switzerland.
| |
Collapse
|
4
|
Korach J, Turner S, Milenkova T, Alecu I, McMurtry E, Bloomfield R, Pujade-Lauraine E. Incidence of myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML) in patients (pts) with a germline (g) BRCA mutation (m) and platinum-sensitive relapsed ovarian cancer (PSR OC) receiving maintenance olaparib in SOLO2: Impact of prior lines of platinum therapy. J Clin Oncol 2018. [DOI: 10.1200/jco.2018.36.15_suppl.5548] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
- Jacob Korach
- Sheba Medical Center, Tel Aviv University, Tel Hashomer, Israel
| | | | | | | | | | | | | |
Collapse
|
5
|
Alecu I, Milenkova T, Turner SR. Risk of severe hematologic toxicities in cancer patients treated with PARP inhibitors: results of monotherapy and combination therapy trials. Drug Des Devel Ther 2018; 12:347-348. [PMID: 29505040 PMCID: PMC5826089 DOI: 10.2147/dddt.s156746] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Download PDF] [Subscribe] [Scholar Register] [Indexed: 12/04/2022]
Affiliation(s)
- Iulian Alecu
- Research and Development, AstraZeneca UK Limited, Cambridge, UK
| | | | - Simon R Turner
- Research and Development, AstraZeneca UK Limited, Cambridge, UK
| |
Collapse
|
6
|
Schofield J, Steiner R, Liu Y, Hobkirk J, Siahmansur T, Pemberton P, Azmi S, Alecu I, Whitelaw D, Carroll S, von Eckardstein A, Hornemann T, Soran H. Sphingolipids and deoxysphingolipids in diabetes. Atherosclerosis 2016. [DOI: 10.1016/j.atherosclerosis.2016.09.054] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
7
|
Verstovsek S, Mesa RA, Martino B, Kiladjian JJ, Jones MM, He S, Habr D, Alecu I, Vannucchi AM. Ruxolitinib safety experience in the polycythemia vera clinical trial program. J Clin Oncol 2015. [DOI: 10.1200/jco.2015.33.15_suppl.e18082] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
| | | | - Bruno Martino
- Ospedale Bianchi-Melacrino-Morelli, Reggio Calabria, Italy
| | | | | | - Shui He
- Incyte Corporation, Wilmington, DE
| | - Dany Habr
- Novartis Pharmaceuticals, East Hanover, NJ
| | | | | |
Collapse
|
8
|
Dohrn MF, Othman A, Hirshman SK, Bode H, Alecu I, Fähndrich E, Karges W, Weis J, Schulz JB, Hornemann T, Claeys KG. Elevation of plasma 1-deoxy-sphingolipids in type 2 diabetes mellitus: a susceptibility to neuropathy? Eur J Neurol 2015; 22:806-14, e55. [DOI: 10.1111/ene.12663] [Citation(s) in RCA: 38] [Impact Index Per Article: 4.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/19/2014] [Accepted: 11/28/2014] [Indexed: 12/31/2022]
Affiliation(s)
- M. F. Dohrn
- Department of Neurology; RWTH Aachen University; Aachen Germany
- Institute of Neuropathology; RWTH Aachen University; Aachen Germany
| | - A. Othman
- Institute of Clinical Chemistry; University Hospital Zürich; Zürich Switzerland
- Centre for Integrative Human Physiology; University of Zürich; Zürich Switzerland
| | - S. K. Hirshman
- Department of Neurology; RWTH Aachen University; Aachen Germany
| | - H. Bode
- Institute of Clinical Chemistry; University Hospital Zürich; Zürich Switzerland
- Centre for Integrative Human Physiology; University of Zürich; Zürich Switzerland
| | - I. Alecu
- Institute of Clinical Chemistry; University Hospital Zürich; Zürich Switzerland
- Centre for Integrative Human Physiology; University of Zürich; Zürich Switzerland
| | - E. Fähndrich
- Division of Endocrinology and Diabetes; RWTH Aachen University; Aachen Germany
| | - W. Karges
- Division of Endocrinology and Diabetes; RWTH Aachen University; Aachen Germany
| | - J. Weis
- Institute of Neuropathology; RWTH Aachen University; Aachen Germany
- JARA - Translational Brain Medicine; Aachen Germany
| | - J. B. Schulz
- Department of Neurology; RWTH Aachen University; Aachen Germany
- JARA - Translational Brain Medicine; Aachen Germany
| | - T. Hornemann
- Institute of Clinical Chemistry; University Hospital Zürich; Zürich Switzerland
- Centre for Integrative Human Physiology; University of Zürich; Zürich Switzerland
| | - K. G. Claeys
- Department of Neurology; RWTH Aachen University; Aachen Germany
- Institute of Neuropathology; RWTH Aachen University; Aachen Germany
- JARA - Translational Brain Medicine; Aachen Germany
| |
Collapse
|
9
|
Cretu D, Iova AR, Alecu I. Researches on the consumers’ behaviour of organic food. Case study, Romania–Bulgaria cross border area. J Biotechnol 2014. [DOI: 10.1016/j.jbiotec.2014.07.198] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/24/2022]
|
10
|
Jaulent MC, Alecu I. Evaluation of an ontological resource for pharmacovigilance. Stud Health Technol Inform 2009; 150:522-526. [PMID: 19745366] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 05/28/2023]
Abstract
In this work, we present a methodology for evaluating an ontology designed in a previous study to describe adverse drug reactions. We evaluate it in term of its fitness for grouping cases in pharmacovigilance. We define as gold standard the Standardized MedDRA Queries (SMQs) developed manually to group terms representing similar medical conditions. We perform an automatic search in the ontology in order to retrieve concepts related to the medical conditions. An optimal query is built for each medical condition. The evaluation relies on the comparison between the terms in the SMQ and the terms subsumed by the query. The result is quantified by sensitivity and specificity. We applied this methodology for 24 SMQs and we obtain a mean sensitivity of 0.82. This work allows validating the semantic resource and provides, in perspective, tools to maintain the ontology while the knowledge is evolving.
Collapse
|
11
|
Abstract
BACKGROUND WHO-ART and MedDRA are medical terminologies used for the coding of adverse drug reactions in pharmacovigilance databases. MedDRA proposes 13 Special Search Categories (SSC) grouping terms associated to specific medical conditions. For instance, the SSC "Haemorrhage" includes 346 MedDRA terms among which 55 are also WHO-ART terms. WHO-ART itself does not provide such groupings. Our main contention is the possibility of classifying WHO-ART terms in semantic categories by using knowledge extracted from SNOMED CT. A previous paper presents the way WHO-ART term definitions have been automatically generated in a description logics formalism by using their corresponding SNOMED CT synonyms. Based on synonymy and relative position of WHO-ART terms in SNOMED CT, specialization or generalization relationships could be inferred. This strategy is successful for grouping the WHO-ART terms present in most MedDRA SSCs. However the strategy failed when SSC were organized on other basis than taxonomy. METHODS We propose a new method that improves the previous WHO-ART structure by integrating the associative relationships included in SNOMED CT. RESULTS The new method improves the groupings. For example, none of the 55 WHO-ART terms in the Haemorrhage SSC were matched using the previous method. With the new method, we improve the groupings and obtain 87% coverage of the Haemorrhage SSC. CONCLUSION SNOMED CT's terminological structure can be used to perform automated groupings in WHO-ART. This work proves that groupings already present in the MedDRA SSCs (e.g. the haemorrhage SSC) may be retrieved using classification in SNOMED CT.
Collapse
Affiliation(s)
- Iulian Alecu
- Université Paris Descartes, Faculté de Médecine; Inserm, U729; SPIM, Paris, 75006 France
| | - Cedric Bousquet
- Université Paris Descartes, Faculté de Médecine; Inserm, U729; SPIM, Paris, 75006 France
| | | |
Collapse
|
12
|
Bousquet C, Alecu I, Jaulent MC. Terminological Reasoning and Signal Detection: Past, Present and Future. Drug Saf 2007. [DOI: 10.2165/00002018-200730100-00020] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/02/2022]
|
13
|
Alecu I, Bousquet C, Degoulet P, Jaulent MC. PharmARTS: terminology web services for drug safety data coding and retrieval. Stud Health Technol Inform 2007; 129:699-704. [PMID: 17911807] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 05/17/2023]
Abstract
MedDRA and WHO-ART are the terminologies used to encode drug safety reports. The standardisation achieved with these terminologies facilitates: 1) The sharing of safety databases; 2) Data mining for the continuous reassessment of benefit-risk ratio at national or international level or in the pharmaceutical industry. There is some debate about the capacity of these terminologies for retrieving case reports related to similar medical conditions. We have developed a resource that allows grouping similar medical conditions more effectively than WHO-ART and MedDRA. We describe here a software tool facilitating the use of this terminological resource thanks to an RDF framework with support for RDF Schema inferencing and querying. This tool eases coding and data retrieval in drug safety.
Collapse
|
14
|
Alecu I, Bousquet C, Mougin F, Jaulent MC. Mapping of the WHO-ART terminology on Snomed CT to improve grouping of related adverse drug reactions. Stud Health Technol Inform 2006; 124:833-8. [PMID: 17108616] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 05/12/2023]
Abstract
The WHO-ART and MedDRA terminologies used for coding adverse drug reactions (ADR) do not provide formal definitions of terms. In order to improve groupings, we propose to map ADR terms to equivalent Snomed CT concepts through UMLS Metathesaurus. We performed such mappings on WHO-ART terms and can automatically classify them using a description logic definition expressing their synonymies. Our gold standard was a set of 13 MedDRA special search categories restricted to ADR terms available in WHO-ART. The overlapping of the groupings within the new structure of WHO-ART on the manually built MedDRA search categories showed a 71% success rate. We plan to improve our method in order to retrieve associative relations between WHO-ART terms.
Collapse
Affiliation(s)
- Iulian Alecu
- INSERM U729, Université Paris Descartes, Faculté de Médecine, Paris, France.
| | | | | | | |
Collapse
|